Riociguat


Thông tin kê toa tóm tắt
Chỉ định/Công dụng
Listed in Dosage.
Liều dùng/Hướng dẫn sử dụng
Adult : PO Pulmonary arterial hypertension; Chronic thromboembolic pulmonary hypertension Dosage is individualised based on patient’s response and tolerance: Initial: 0.5-1 mg tid for 2 weeks, increase in increments of 1.5 mg daily at 2 weeks interval. Max dose: 2.5 mg tid.
Dosage Details
Oral
Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension
Adult: Dosage is individualised based on patient’s response and tolerance: Initially, 0.5-1 mg tid, approximately 6-8 hours apart for 2 weeks. Increase dose in increments of 1.5 mg daily at 2 weeks interval up to Max 2.5 mg tid if systolic blood pressure ≥95 mmHg and no hypotension. Decrease dose by 0.5 mg tid if hypotension occurs. If treatment is interrupted for ≥3 days, retitrate from the initial dose.
Special Patient Group
Current smokers: Increase dose up to Max 2.5 mg tid.
Patients taking strong CYP and P-gp/BRCP inhibitors (e.g. azole antifungals or protease inhibitors): Initially, 0.5 mg tid.
Hepatic Impairment
Severe (Child Pugh C): Contraindicated.
Chống chỉ định
Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP). Severe hepatic impairment (Child Pugh C). Pregnancy and lactation. Concomitant use with nitrates or nitric acid donors, phosphodiesterase (PDE-5) inhibitors (e.g. sildenafil, tadanafil, vardenafil).
Thận trọng
Patient with pulmonary veno-occlusive disease (PVOD), systolic blood pressure <95 mm Hg, hypovolaemia, severe left-ventricular outflow obstruction, autonomic dysfunction, history of serious haemoptysis or bronchial arterial embolization surgery. Smokers. Renal and mild to moderate hepatic impairment.
Phản ứng phụ
Significant: Hypotension, pulmonary oedema.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Palpitations.
Gastrointestinal disorders: Dyspepsia, nausea, diarrhoea, vomiting, gastroenteritis, gastritis, GERD, dysphagia, abdominal pain, constipation, abdominal distention.
General disorders and administration site conditions: Peripheral oedema.
Nervous system disorders: Headache, dizziness.
Respiratory, thoracic and mediastinal disorders: Epistaxis, nasal congestion.
Potentially Fatal: Serious bleeding (e.g. haemoptysis, pulmonary haemorrhage).
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness and dizziness, if affected, do not drive of operate machinery.
MonitoringParameters
Monitor blood pressure; perform pregnancy test prior to and throughout treatment duration; screen for smoking. Monitor signs and symptoms of hypotension, bleeding, and pulmonary oedema.
Quá liều
Symptoms: Pronounced hypotension. Management: Supportive treatment.
Tương tác
Decreased serum concentration with antacids, PPI, CYP3A4 inducers (e.g. phenytoin, rifampicin). Increased plasma concentration with CYP1A1 (e.g. erlotinib), CYP3A4 inhibitors (e.g. clarithromycin), potent P-gp/BCRP inhibitors (e.g. ciclosporin, azole antifungals, protease inhibitors).
Potentially Fatal: Enhanced hypotensive effect with amyl nitrate, nitroglycerin, PDE-5 inhibitors (e.g. sildenafil, tadanafil, vardenafil).
Food Interaction
Decreased serum concentration with St. John’s wort.
Tác dụng
Description: Riociguat is a soluble guanylate cyclase(sGC) stimulator. It sensitise sGC to endogenous nitric oxide (NO) by stabilising the NO-sGC binding and directly stimulates sGC independent of NO, leading to increased cyclic guanosine monophosphate (cGMP) generation, thereby producing vasodilation and reducing pulmonary artery pressure.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Absolute bioavailability: Approx 94%. Time to peak plasma concentration: Approx 1.5 hours.
Distribution: Volume of distribution: Approx 30 L. Plasma protein binding: Approx 95% mainly to serum albumin and α1-acid glycoprotein.
Metabolism: Metabolised by CYP1A1, 3A4, 2C8, 2J2 enzymes to an active metabolite, M1, then further metabolised to an inactive metabolite, N-glucuronide.
Excretion: Via faeces (approx 53%); urine (approx 40%). Elimination half-life: Approx 7 hours.
Đặc tính

Chemical Structure Image
Riociguat

Source: National Center for Biotechnology Information. PubChem Database. Riociguat, CID=11304743, https://pubchem.ncbi.nlm.nih.gov/compound/Riociguat (accessed on Jan. 23, 2020)

Bảo quản
Store at 25°C.
Follow applicable procedures for receiving, handling, administration, and disposal. Wear gloves during receiving, unpacking, and placing in storage.
Phân loại MIMS
Phân loại ATC
C02KX05 - riociguat ; Belongs to the class of other antihypertensives. Used in the treatment of pulmonary arterial hypertension.
References
Adempas Tablet, Film-Coated (Bayer HealthCare Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 02/03/2018.

Anon. Riociguat. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/03/2018.

Buckingham R (ed). Riociguat. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/03/2018.

Joint Formulary Committee. Riociguat. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/03/2018.

McEvoy GK, Snow EK, Miller J et al (eds). Riociguat. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 02/03/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Riociguat từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2020 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in